National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 7 of 1990)

Overview

The National Health Act 1953 was enacted by the Parliament of Australia to provide for the administration of national health and medical research schemes, and for related purposes. The Act was designed to fill the gap in comprehensive national health legislation, thereby establishing a framework for the provision of health services and the administration of health-related benefits across the country. The Act aims to ensure that the Australian community has access to necessary health services and benefits, thereby promoting overall public health. In this context, the Pharmaceutical Benefits Declaration under sub-section 85(2AA), made by Margaret Nona Ford as the Principal Advisor for the Health Care Access Division within the Department of Community Services and Health, serves to identify specific drugs and medicinal preparations that will no longer be subject to the provisions of Part VII of the Act, thereby refining the scope of pharmaceutical benefits provided under the scheme.

Scope and Application

The National Health Act 1953, as amended by the Pharmaceutical Benefits Declaration under sub-section 85(2AA) No. PB7 of 1990, applies to specified drugs and medicinal preparations listed in the Schedule of the Declaration. This legislative instrument removes the applicability of Part VII of the National Health Act 1953 to the specified drugs and medicinal preparations, effective from 1 December 1990. The declaration specifies that Hydrocortisone Acetate with Neomycin Sulphate, Kaolin, Light or Light Kaolin (Natural) with Pectin, and Polymyxin B Sulphate with Bacitracin and Neomycin Sulphate are no longer subject to the provisions outlined in Part VII of the Act. The geographic reach of this legislation is national, extending throughout the Commonwealth of Australia. There are no exclusions, exemptions, or thresholds specified within the text of this particular declaration. The application of the Act may be further extended or restricted through subordinate instruments, which would need to be referred to for more detailed understanding.

Key Provisions

The main operative sections of this declaration under sub-section 85(2AA) of the National Health Act 1953 (section 85(2AA)) specify that certain drugs and medicinal preparations will cease to be subject to Part VII of the Act. This Part generally deals with the regulation of therapeutic goods, including prescription medicines. The declaration, which came into effect on 1 December 1990 (section 1), lists specific drugs that are to be excluded from the regulatory scope of Part VII (section 2). These drugs include Hydrocortisone Acetate with Neomycin Sulphate, Kaolin, Light or Light Kaolin (Natural) with Pectin, and Polymyxin B Sulphate with Bacitracin and Neomycin Sulphate (Schedule). The obligations and requirements imposed by this Act on the parties or entities it governs are primarily concerned with ensuring that the specified drugs are no longer subject to the regulatory provisions outlined in Part VII. For example, these drugs will no longer need to meet the standards for inclusion in the Australian Register of Therapeutic Goods. Additionally, entities that manufacture, supply, or advertise these drugs will no longer be required to comply with certain regulatory requirements such as quality control standards, labelling, and advertising restrictions that typically apply under Part VII. In terms of potential consequences for breach, the Act does not explicitly detail specific offences, penalties, or civil/criminal consequences for non-compliance with this declaration. However, general provisions within the National Health Act 1953 apply. For example, contraventions of the Act can result in civil penalties, which may include fines up to a significant amount determined by the severity of the breach. Criminal penalties can also apply, potentially including imprisonment, for more severe breaches that involve intentional or reckless disregard of the Act's provisions. The exact penalties depend on the nature and extent of the breach, and are outlined in other sections of the National Health Act 1953.